A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Prior treatment

• Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed.

Other illness

• History of or positive test result for human immunodeficiency virus, hepatitis C virus antibody or hepatitis B virus.

Other

• Documented p.F21C SOD1 mutation.
• Current enrollment in any other interventional study.
• Pregnant or currently breastfeeding.

• Voluntarily consents to participate in this study and provides written informed consent prior to the start of any study specific procedures.
• ≥ 18 years of age at the time of informed consent.
• Diagnosis of possible, laboratory supported probable, probable, or definite ALS according to the World Federation of Neurology El Escorial.
• Documented SOD1 mutation.
• Forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and height (measured seated).
• If taking riluzole or edaravone, subject must be on a stable dose or ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit.